Sichuan Kelun-Biotech Announces Board Changes and Governance Amendments

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced proposed changes to its board of directors and amendments to its Articles of Association. The company plans to elect new directors for the fourth session of the board, including the introduction of an employee representative director role. These changes are part of the company’s efforts to align with recent amendments to China’s Company Law and are subject to shareholder approval at the upcoming AGM. The retirement of a current director and the removal of the Supervisory Committee are also part of the proposed amendments, which aim to streamline governance and enhance employee representation.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of innovative drugs and therapies. The company is involved in the biopharmaceutical industry, providing products and services aimed at addressing various medical needs.

YTD Price Performance: 59.22%

Average Trading Volume: 372,172

Technical Sentiment Signal: Sell

Current Market Cap: HK$57.94B

See more data about 6990 stock on TipRanks’ Stock Analysis page.